Results 211 to 220 of about 106,894 (260)

Prediction of no-reflow phenomenon in elective percutaneous coronary intervention for non-acute myocardial infarction. [PDF]

BMC Cardiovasc Disord
Jeon HS, Youn YJ, Lee TS, Kim SY, Lee SJ, Kim SE, Lee JH, Park YJ, Son JW, Lee JW, Ahn MS, Ahn SG, Kim JY, Yoo BS.   +13 more
europepmc   +1 more source

Coronary angiography-derived microcirculatory resistance predicts adverse cardiovascular events in elderly with unstable angina post-percutaneous coronary intervention. [PDF]

Front Aging
Li K, Wang L, Liao P, Hu Y, Xiong L.
europepmc   +1 more source

Multimodality Imaging of Intramyocardial Dissecting Hematoma: A Rare, Potentially Fatal Complication of Percutaneous Coronary Intervention. [PDF]

JACC Case Rep
van Cauteren YJM, Smulders MW, Mihl C, Gommers S, Bijvoet GP, Lux Á, Theunissen RALJ.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Percutaneous Coronary Intervention in 2018

JAMA - Journal of the American Medical Association, 2018
exaly   +3 more sources

Percutaneous Intervention of Coronary Aneurysm

Cardiovascular Revascularization Medicine, 2020
The coronary artery aneurysm (CAA) is not a frequent condition in the catheterization laboratory. The management is uncertain. Most of the cases, the treatment is surgical with good results. In smaller aneurysm, the use of covered stents is an alternative. This is an anterograde approach CTO (chronic total occlusion) case of a middle segment RCA (right
Pablo, Antileo, Christian, Dauvergne, Manuel, Méndez, Marcio, Alvarado, Óscar, Sepúlveda, Rodrigo, Monsalve, Jorge, Sandoval   +6 more
openaire   +2 more sources

Cangrelor in percutaneous coronary intervention

Expert Review of Clinical Pharmacology, 2009
Cangrelor is a novel, intravenous P2Y12 receptor antagonist in development for use in percutaneous coronary intervention. Currently in Phase III testing, the reversible platelet inhibitor provides several inherent advantages over other P2Y12 receptor antagonists in this setting for the prevention of adverse cardiac events.
Julie H, Oestreich, Steven R, Steinhubl
openaire   +2 more sources

Bivalirudin in percutaneous coronary intervention

American Journal of Health-System Pharmacy, 2003
The chemistry and pharmacology, pharmacokinetics, pharmacodynamics, adverse effects, drug interactions, dosing and administration, and pharmacoeconomics of bivalirudin are reviewed; clinical trials of bivalirudin's application in percutaneous coronary intervention (PCI) are also discussed.
Michael F, Caron, George R, McKendall
openaire   +2 more sources